Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

AstraZeneca

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00240344

NL401142

REALISTIC

Details and patient eligibility

About

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Enrollment: 2,650 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• High risk patients
• High doses of other statins
• LDL-C known, starts with Crestor 10 mg
• Permission to use patient data by AstraZeneca (AZ)